viewJohnson & Johnson

Johnson & Johnson receives US approval for COVID-19 vaccine, to test it on babies

The authorisation is expected to boost the country's immunisation programme

Johnson & Johnson - Johnson & Johnson receives US approval for COVID-19 vaccine, to test it on babies

Johnson & Johnson (NYSE:JNJ) has announced its one-shot COVID-19 vaccine has been approved by the US Food and Drug Administration.

Developed by the Belgian arm Janssen, it is now available for individuals 18 years of age and older after it was shown to be 85% effective in late-stage clinical trials.

READ: What sets Johnson & Johnson’s vaccine apart from those already in circulation

The terms of the Emergency Use Authorisation allow the government to roll it out while more data is gathered to issue a full approval, accelerating the immunisation programme.

The company has begun shipping its COVID-19 vaccine and expects to deliver 20mln doses to the US by the end of the month, rising to 100mln during the first half of 2021.

It is awaiting approval from the European Medicines Agency and the World Health Organisation.

J&J is also planning to test the inoculation on babies and pregnant women, The New York Times reported.

The formulation is developed Janssen’s AdVac technology, which uses a genetically modified version of the common cold virus (adenovirus) so it can no longer replicate in humans and cause disease.

It can remain stable for two years at -20°C and at least three months at 2-8°C, so it’s compatible with standard distribution channel without the need for extra infrastructure.

Shares rose 2% to US$160.98 on Monday at the opening bell.

Quick facts: Johnson & Johnson


Price: 164.86 USD

Market Cap: $433.99 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Ananda Developments (AQSE: ANA) presenting at the Proactive One2One Virtual...

Ananda Developments (AQSE:ANA) (AQSE: ANA) presenting at the Proactive One2One Virtual Forum - September 2021 Ananda Developments is listed on the AQSE Growth Market in London and provides a UK based listed platform for cannabis investors to gain exposure to the sector. We believe that the...

1 hour, 24 minutes ago

2 min read